Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old
- 1 September 2004
- journal article
- clinical trial
- Published by Elsevier in Leukemia Research
- Vol. 28 (9) , 909-919
- https://doi.org/10.1016/j.leukres.2003.12.012
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- The Cytotoxicity of Arsenic Trioxide to Normal Hematopoietic Progenitors and Leukemic Cells is Dependent on Their Cell-cycle StatusLeukemia & Lymphoma, 2002
- Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemiaLeukemia, 2000
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideNew England Journal of Medicine, 1998
- Proteases to die forGenes & Development, 1998
- Phenylarsine oxide augments tyrosine phosphorylation in hematopoietic cellsEuropean Journal of Haematology, 1992
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- History of the Treatment of Chronic Myelocytic LeukemiaThe Lancet Healthy Longevity, 1988
- Daunorubicin in patients with relapsed and refractory acute nonlymphoblastic leukemia previously treated with anthracyclineAmerican Journal of Hematology, 1988
- PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIALThe Lancet, 1986
- Action of Iron, Cod-liver Oil, and Arsenic on the Globular Richness of the BloodThe Lancet Healthy Longevity, 1878